Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Semaglutide Wegovy / Ozempic Mechanism: GLP-1 receptor agonist (single target) Weight loss: ~15-17% body weight (STEP trials, 68 weeks) Dosing: Weekly injection, titrated from 0.25mg to 2.4mg Common side effects: Nausea, vomiting, diarrhea, constipation (typically transient) Availability: Longer track record, more widely available Cardiovascular data: SELECT trial demonstrated 20% reduction in major cardiovascular events Tirzepatide Zepbound / Mounjaro Mechanism: Dual GLP-1 + GIP receptor agonist (two targets) Weight loss: ~20-22% body weight (SURMOUNT trials, 72 weeks) Dosing: Weekly injection, titrated from 2.5mg to 15mg Common side effects: Similar GI profile to semaglutide
If you miss a dose within five days, take it immediately when you remember
Ozempic Sulfur Burps, Gas, and Bloating: Why GLP-1 Medications Cause the Food-Stuck Feeling Joshua Silva, MD Jan 26 8 min read Updated: Feb 4 Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD Many people taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) experience digestive symptoms including bloating, sulfur-smelling burps, excess gas, early satiety, or a heavy sensation that food feels stuck after meals
doi:10.1056/NEJMoa1109400
The study found an association rather than a guaranteed protective effect, and an individuals overall risk depends far more on liver disease, viral hepatitis, alcohol use, metabolic health and family medical history
